Novescia is one of France’s leading routine diagnostics groups, currently comprising some 80 laboratories. Since its creation in 2008, the group has achieved very fast growth and has been able to successfully close a significant amount of acquisitions in France, thanks to an innovative business model combining a true partnership with biologists and an industrial approach.

Cobepa's investment is intended to support the group’s further growth and development, in partnership with its management team and the existing shareholders.

Cobepa now controls indirectly 10% of the share capital of Novescia, whilst the existing shareholders have also subscribed massively to the current funding round.